ASSOCIATION OF POLYMORPHISM RS3846663 IN HMG-CoA REDUCTASE GENE WITH THE EFFECTIVENESS OF STATIN THERAPY IN PATIENTS WITH CORONARY HEART DISEASE

• Main Authors: Aleksey Vladimirovich Osedko, Michael Yurevich Kotlovskiy, Olga Yakovlevna Osedko, Alexander Mikhaylovich Dygai
• Format: Article
• Language: English
• Published: Science and Innovation Center Publishing House 2019-05-01
• Series: Siberian Journal of Life Sciences and Agriculture
• Subjects: ГМГ-КоА-редуктаза; симвастатин; ишемическая болезнь сердца; гиперхолестеринемия; rs3846663; холестерин
• Online Access: http://journal-s.org/index.php/vmno/article/view/12074

The purpose of this work was to study the associations of RS3846663 variants in the HMG-CoA reductase gene with effectiveness of statin therapy. For the coronary heart disease patients group, 127 subjects (59 females and 68 males) were selected. In order to identify single nucleotide polymorphism, minisequencing was applied with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-ToF/MS) for subsequent detection of the reaction products. In this study, the statin significantly reduced total cholesterol, low density lipoprotein and triglyceride levels, both after one month and two months of treatment. It was established that carrying CC and TT genotypes of RS3846663 in HMG-CoA reductase gene had no impact on the change in total cholesterol and almost all values in the spectrum of lipoproteins during statin therapy, regardless of its duration. A weak tendency to an increase in high-density lipoproteins was observed in heterozygous CT carriers after one month of statin treatment. In addition, no significant association was found between carrying heterozygous CT genotype and TT homozygote and achievement of target levels of lipoproteins and total cholesterol during simvastatin treatment, regardless of its duration.